ABBV AbbVie Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ABBV

Price (delayed)

$108.08

Market cap

$191B

P/E Ratio

29.45

Dividend/share

$5.08

EPS

$3.67

Enterprise value

$264.59B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter
ABBV's gross profit is up by 32% year-on-year and by 8% since the previous quarter
The EPS has grown by 32% from the previous quarter but it has contracted by 22% YoY
The company's net income rose by 29% QoQ but it fell by 4.2% YoY
AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter
The gross margin has contracted by 11% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.abbvie.com/
Peers: PFE BMY LLY AMGN

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$191B
Enterprise value
$264.59B
Valuations
Price to earnings (P/E)
29.45
Price to book (P/B)
15.19
Price to sales (P/S)
3.56
EV/EBIT
31.21
EV/EBITDA
15.34
EV/Sales
4.92
Earnings
Revenue
$53.73B
EBIT
$8.48B
EBITDA
$17.25B
Free cash flow
$19.57B
Per share
EPS
$3.67
Free cash flow per share
$11.06
Book value per share
$7.12
Revenue per share
$30.37
TBVPS
$20.48
Balance sheet
Total assets
$147.97B
Total liabilities
$135.38B
Debt
$82.14B
Equity
$12.57B
Working capital
-$2.69B
Liquidity
Debt to equity
6.53
Current ratio
0.91
Quick ratio
0.65
Net debt/EBITDA
4.27
Margins
EBITDA margin
32.1%
Gross margin
65.6%
Net margin
12.4%
Operating margin
28.9%
Efficiency
Return on assets
4.5%
Return on equity
48.8%
Return on invested capital
10.2%
Return on capital employed
7.1%
Return on sales
15.8%
Dividend
Dividend yield
4.7%
DPS
$5.08
Payout ratio
138.4%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
0.29%
1 week
0.76%
1 month
-8.72%
1 year
20.38%
YTD
0.87%
QTD
-4.05%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$53.73B
Gross profit
$35.26B
Operating income
$15.55B
Net income
$6.66B
Gross margin
65.6%
Net margin
12.4%
ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter
The operating income has grown by 42% YoY and by 31% from the previous quarter
The net margin has declined by 35% year-on-year but it rose by 20% since the previous quarter
ABBV's gross profit is up by 32% year-on-year and by 8% since the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
29.45
P/B
15.19
P/S
3.56
EV/EBIT
31.21
EV/EBITDA
15.34
EV/Sales
4.92
The EPS has grown by 32% from the previous quarter but it has contracted by 22% YoY
ABBV's P/E is 25% above its 5-year quarterly average of 23.5 but 7% below its last 4 quarters average of 31.8
AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter
ABBV's price to book (P/B) is 12% higher than its last 4 quarters average of 13.6
ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter
ABBV's P/S is 13% below its 5-year quarterly average of 4.1 and 6% below its last 4 quarters average of 3.8

Efficiency

How efficient is AbbVie business performance
The ROS has contracted by 39% YoY but it has grown by 20% from the previous quarter
AbbVie's return on assets has decreased by 37% YoY but it has increased by 32% QoQ
The ROE has grown by 34% from the previous quarter
AbbVie's ROIC has increased by 31% from the previous quarter but it has decreased by 31% YoY

Dividends

What is ABBV's dividend history
DPS
$5.08
Dividend yield
4.7%
Payout ratio
138.4%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 9% higher than its total liabilities
The quick ratio has grown by 12% YoY and by 7% from the previous quarter
ABBV's current ratio is up by 10% since the previous quarter and by 6% year-on-year
AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter
The company's debt to equity rose by 10% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.